Biosimilars Global Market Opportunities And Strategies To 2031

Biosimilars Market 2022 – By Type (Monoclonal Antibodies, Insulin, Erythropoietin, Granulocyte-Colony Stimulating Factor, Other Hormones), By Application (Oncology, Chronic And Autoimmune Diseases, Growth Hormone Deficiency, Infectious Diseases), And By Region, Opportunities And Strategies – Global Forecast To 2031

Name: Biosimilars Global Market Opportunities And Strategies To 2031
Creator: The Business Research Company
License: https://www.thebusinessresearchcompany.com/privacy-policy

Biosimilars Global Market Opportunities And Strategies To 2031

Starting Price : $5000.00 $3500.00 | Pages : 287 | Published : July 2022 | | Format : pdf

Purchase Options

Request a Sample

Request For Discount

Customise Your Report

Item added to cart!

Request For Proposal

Request For Regional Data

Need assistance or more information before the purchase?

Enquire Before Buying

Proud Members Of

Biosimilars Market Definition

The biosimilars market consists of sales of biosimilars and related services that are used to treat chronic diseases such as diabetes, arthritis, and cancer. Biosimilars are pharmaceutical medicines that are manufactured using cell lines and which have been shown not to have any clinically meaningful differences from the originator or reference medicine in terms of quality, safety and efficacy. Biosimilars can only be authorized once the period of data exclusivity on the reference biological medicine has expired.

Book your 30 minutes free consultation with our research experts

Biosimilars Market Size

The global biosimilars market size reached a value of nearly $11,418.9 million in 2021, having grown at a compound annual growth rate (CAGR) of 34.8% since 2016. The market is expected to grow from $11,418.9 million in 2021 to $25,985.2 million in 2026 at a rate of 17.3%. The market is then expected to grow at a CAGR of 18.0% from 2026 and reach $59,555.8 million in 2031.

Growth in the historic period resulted from an increase in cancer prevalence, strong economic growth in emerging markets, an increase in pharmaceutical R&D expenditure, increased healthcare expenditure, growing government initiatives, strong pipeline of drugs, low cost of biosimilars and an increase in patent expiration. Factors that negatively affected growth in the historic period were regulatory changes, low healthcare access, lack of awareness on biosimilars among primary care physicians and specialists, reimbursement challenges, the coronavirus pandemic and low healthcare reimbursements.

Going forward, increasing prevalence of cancer, increasing demand for prophylaxis with granulocyte colony-stimulating factor (G-CSF), a rise in healthcare expenditure, high potential of emerging economies, technology advances, high penetration of biological drugs, aging population and an increase in healthcare access will drive the growth. Factors that could hinder the growth of the biosimilars market in the future include high costs of drugs, high cost of drug development with threat of failure, pricing pressures from regulators and insufficient and outdated health system.

Biosimilars Market Drivers

The key drivers of the biosimilars market include:

High Penetration Of Biological Drugs

High penetration of the biologics is expected to be a driver of market growth during this period. Pharmaceutical companies are shifting towards originator biologics and competitive biosimilar drug development.

Pharma companies had focused on small molecules for decades, but the rate of innovation in that field has slowed dramatically, leading to the shift towards biologics. These research and development (R&D) activities have led to increasing success rates in clinical trials. R&D is being carried out by market leaders as they continuously strive to make breakthroughs in the form of new and effective biologics. This flow of originator biologics will provide the future substrate for biosimilar market growth

For instance, Amgen and Kirin Holdings Company are developing a filgrastim biosimilar which stimulates the growth of white blood cells to treat neutropenia, a common adverse event in patients receiving chemotherapy for breast cancer. Currently, the drug is in Phase I/II clinical study for breast cancer patients.

In April 2022, the US Food and Drug Administration (FDA) approve the Biologics License Application (BLA) from Amneal Pharmaceuticals Inc for bevacizumab-maly, a biosimilar referencing Avastin, the Roche/Genentech product. Therefore, high penetration of the biosimilar drugs is expected to drive the growth of the biosimilars market. Furthermore, the future growth of biosimilars will be on the back of new originator molecules or biologics.

Biosimilars Market Restraints

The key restraints on the biosimilars market include:

Insufficient And Outdated Health System

Insufficient and outdated health system infrastructure (facilities, technology, clinicians) remains, for many, a major hurdle to achieving health equity.

Fewer than 50% of Africans have access to modern health facilities. Further, around 61% of births were attended by skilled health staff in 2018, far fewer than the 80% global average. And although more people in India’s smaller towns and rural areas now have money for health care through the new PMSBY insurance scheme, they have limited options to use it because clinician and product supply is limited, and government health facilities are few and far between.

As of 2019, 9.6% of the 24,855 primary health centers (PHCs) in India had no doctor, 38.4% had no laboratory technician, and 23.9% had no pharmacist. There are also severe gaps in skilled professionals: For rural community health centers in 2019, only 15% of the surgical posts, 13% of the physician posts, 25% of the obstetrics and gynecology posts, and 20% of the pediatrician posts were filled.

Biosimilars Market Trends

Major trends shaping the biosimilars market include:

Robust Research & Development

The biosimilars market is witnessing robust research and development activities. These research and development activities have led to increasing success rates in clinical trials. Research and development is being carried out by market leaders in the biosimilars market as they continuously strive to make breakthroughs in the form of new and effective drugs.

In June 2020, Pfizer, an American multinational pharmaceutical company, received approval from the US Food and Drug Administration to introduce its biosimilar pegfilgrastim medicine Nyvepria for lowering the incidence of infection as manifested by febrile neutropenia in patients with nonmyeloid malignancies receiving myelosuppressive anticancer drugs.

In May 2021, Zydus Cadila, launched the world’s first biosimilar antibody-drug conjugate of trastuzumab emtansine. The biosimilar, which uses Genentech/Roche’s trastuzumab emtansine (Kadcyla®) as the reference product, will be marketed under the name Ujvira®.

In March 2020, AzarGen Biotechnologies (Pty) Ltd., a South Africa-based biotechnology company, in collaboration with iBio, Inc., a USA-based biotechnology company initiated its development activities of rituximab biosimilar. AzarGen Biotechnologies is expected to utilize FastPharming System developed by iBio, Inc. to produce rituximab in plants.

Use of Robots and AI

The increasing adoption and use of robotics and artificial intelligence (AI) are key trends gaining popularity in the biosimilars market. Artificial intelligence is intelligence demonstrated by machines and is highly versatile.

Biomanufacturing and the designs of bioprocess facilities as well as associated manufacturing require excessive amounts of manual labor and manual interventions that lead to high labor costs and, consequently, the total cost to supply.

Targeted applications of mobile robots are expected to help decrease the dependency on manual labor and associated costs of biomanufacturing. Robots help execute various routine operations such as material handling, waste handling, material transport, hazardous operations, autonomous operations, and challenging tasks such as precision machining. Furthermore, robots are being developed to be smarter less expensive, and more versatile.

Opportunities And Recommendations In The Biosimilars Market

Opportunities –The top opportunities in the biosimilars market segmented by type will arise in the monoclonal antibodies segment, which will gain $8,508.0 million of global annual sales by 2026. The top opportunities in the biosimilars market segmented by application will arise in the oncology segment, which will gain $6,889.0 million of global annual sales by 2026. The biosimilars market size will gain the most in USA at $6,677.4 million.

Recommendations-To take advantage of the opportunities, The Business Research Company recommends the biosimilars companies to launch new products, invest in robotics and artificial intelligence (AI), expand in emerging markets, scale up through merger and acquisition activity, provide competitively priced offerings, continue to participate in events and conferences, take initiatives to educate consumers, target high-growth application areas and increase strategic partnerships.

Biosimilars Market Segmentation

The biosimilars market is segmented by type and by application.
By Type -
The biosimilars market is segmented by type into

a) Monoclonal Antibodies
b) Insulin
c) Erythropoietin
d) Granulocyte-Colony Stimulating Factor
e) Other Hormones
f) Others

The monoclonal antibodies market was the largest segment of the biosimilars market segmented by type, accounting for 39.6% of the total in 2021. Going forward, the erythropoietin segment is expected to be the fastest growing segment in the biosimilars market segmented by type, at a CAGR of 28.2% during 2021-2026.
By Application –
The biosimilars market is segmented by application into

a) Oncology
b) Chronic And Autoimmune Diseases
c) Growth Hormone Deficiency
d) Infectious Diseases
e) Other Applications

The biosimilars market is segment by geography into
By Geography - The biosimilars market is segment by geography into

• China
• India
• Japan
• Australia
• Indonesia
• South Korea

• USA

• Brazil

• France
• Germany
• UK

• Russia

Western Europe was the largest region in the global biosimilars market, accounting for 66.0% of the total in 2021. It was followed by North America, and then the other regions. Going forward, the fastest-growing regions in the global biosimilars market will be Africa and Eastern Europe where growth will be at CAGRs of 117.0% and 60.1% respectively. These will be followed by South America and Middle East where the markets are expected to grow at CAGRs of 53.854% and 53.851% respectively.

Biosimilars Market Competitive Landscape

Major Competitors are:

Amgen

Pfizer

Novartis AG

Samsung Bioepis Co., Ltd.

Viatris

Other Competitors Include:

Biocon

Celltrion, Inc.

Coherus Biosciences

Elli Lilly and Company

Dr. Reddy's Laboratories

Roche India Pvt Ltd

Abbott India Limited

bioMérieux India

Becton Dickinson Private Limited

Danaher Corporation

Wuxi biologics

shanghai Henlius biotech

Innovent Biologics

Hisun Pharma

3SBio

Beijing ShuangLu Pharmaceuticals

Qilu Pharmaceutical

Shanghai Fosun Pharmaceuticals

Mylan

Kyowa Hakko Kirin

Takeda

Mitsubishi Tanabe

AGC Biologics

Bio-Thera

Sandoz Pty Ltd

Apotex Pty Ltd

Cadila Pharmaceuticals

BiosanaPharma

GlaxoSmithKline

AstraZeneca

Bayer

Merck

Boehringer Ingelheim

Sanofi

Fresenius Kabi

Napp Pharmaceuticals

Mundipharma Deutschland GmbH & Co. KG

HARMONIE MEDICAL SERVICE Saint-Benoît

INSULET FRANCE SAS Paris

Microgen

Geropharm

Valenta

NovaMedica

SynBio

Rani Therapeutics

Emisphere Technologies, Inc.

Enteris BioPharma

Allena Pharmaceuticals

Abbvie

Johnson & Johnson

Biogen Inc.

Aché

Eurofarma

Teva Pharmaceuticals

Oramed Pharmaceuticals

Entera Bio

Julphar

Hikma Pharmaceuticals

BIOPHARMA-MEA

NeoTX

AID Genomics Limited

Altis Biologics

Cipla Medpro South Africa

Next Biosciences

Viome

Inqaba Biotechnical Industries (Pty)

1. Biosimilars Market Executive Summary

2. Table of Contents

3. List of Figures

4. List of Tables

5. Report Structure

6. Introduction and Market Characteristics

6.1. General Market Definition

6.2. Summary

6.3. Market Segmentation By Type

6.3.1. Monoclonal Antibodies

6.3.2. Insulin

6.3.3. Erythropoietin

6.3.4. Granulocyte-Colony Stimulating Factor

6.3.5. Other Hormones

6.3.6. Other Types

6.4. Market Segmentation By Application

6.4.1. Oncology

6.4.2. Chronic and Autoimmune Diseases

6.4.3. Growth Hormone Deficiency

6.4.4. Infectious Diseases

6.4.5. Other Applications

7. Major Market Trends

7.1. Robust Research & Development

7.2. Demand For Biosimilars In The Treatment Of Neutropenia

7.3. Growing Mergers And Acquisitions

7.4. Revised FDA Regulations To Facilitate Biosimilar Drug Development

7.5. Large Number Of Strategic Partnerships

7.6. Increasing Investments In Biosimilars Market

7.7. Use of Robots and AI

8. Global Market Size And Growth

8.1. Market Size

8.2. Historic Market Growth, 2016 – 2021, Value ($ Million)

8.2.1. Market Drivers 2016 – 2021

8.2.2. Market Restraints 2016 – 2021

8.3. Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

8.3.1. Market Drivers 2021 – 2026

8.3.2. Market Restraints 2021 – 2026

9. Global Biosimilars Market Segmentation

9.1. Global Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

9.2. Global Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

10. Biosimilars Market, Regional And Country Analysis

10.1. Global Biosimilars Market, By Region, Historic and Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

10.2. Global Biosimilars Market, By Country, Historic and Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

11. Asia-Pacific Market

11.1.1. Summary

11.2. Market Overview

11.2.1. Region Information

11.2.2. Market Information

11.2.3. Background Information

11.2.4. Government Initiatives

11.2.5. Regulations

11.2.6. Regulatory Bodies

11.2.7. Major Associations

11.2.8. Taxes Levied

11.2.9. Corporate Tax Structure

11.2.10. Investments

11.2.11. Major Companies

11.3. Asia-Pacific Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

11.4. Asia-Pacific Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

11.5. Asia-Pacific Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

11.6. Asia-Pacific Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

11.7. Asia-Pacific Biosimilars Market: Country Analysis

11.8. China Market

11.8.1. Summary

11.9. Market Overview

11.9.1. Country Information

11.9.2. Market Information

11.9.3. Background Information

11.9.4. Government Initiatives

11.9.5. Regulations

11.9.6. Regulatory Bodies

11.9.7. Major Associations

11.9.8. Taxes Levied

11.9.9. Corporate Tax Structure

11.9.10. Investments

11.9.11. Major Companies

11.10. China Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

11.11. China Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

11.12. China Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

11.13. China Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

11.14. India Biosimilars Market

11.15. India Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

11.16. India Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

11.17. India Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

11.18. India Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

11.19. Japan Biosimilars Market

11.20. Japan Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

11.21. Japan Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

11.22. Japan Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

11.23. Japan Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

11.24. Australia Biosimilars Market

11.25. Australia Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

11.26. Australia Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

11.27. Australia Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

11.28. Australia Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

11.29. Indonesia Biosimilars Market

11.30. Indonesia Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

11.31. Indonesia Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

11.32. Indonesia Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

11.33. Indonesia Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

11.34. South Korea Biosimilars Market

11.35. South Korea Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

11.36. South Korea Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

11.37. South Korea Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

11.38. South Korea Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

12. Western Europe Market

12.1.1. Summary

12.2. Market Overview

12.2.1. Region Information

12.2.2. Market Information

12.2.3. Background Information

12.2.4. Government Initiatives

12.2.5. Regulations

12.2.6. Regulatory bodies

12.2.7. Major Associations

12.2.8. Taxes Levied

12.2.9. Corporate Tax Structure

12.2.10. Investments

12.2.11. Major Companies

12.3. Western Europe Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

12.4. Western Europe Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

12.5. Western Europe Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

12.6. Western Europe Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

12.7. Western Europe Biosimilars Market: Country Analysis

12.8. UK Biosimilars Market

12.9. UK Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

12.10. UK Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

12.11. UK Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

12.12. UK Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

12.13. Germany Biosimilars Market

12.14. Germany Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

12.15. Germany Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

12.16. Germany Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

12.17. Germany Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

12.18. France Biosimilars Market

12.19. France Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

12.20. France Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

12.21. France Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

12.22. France Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

13. Eastern Europe Market

13.1.1. Summary

13.2. Market Overview

13.2.1. Region Information

13.2.2. Market Information

13.2.3. Background Information

13.2.4. Government Initiatives

13.2.5. Regulations

13.2.6. Regulatory Bodies

13.2.7. Major Associations

13.2.8. Taxes Levied

13.2.9. Corporate Tax Structure

13.2.10. Investments

13.2.11. Major Companies

13.3. Eastern Europe Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

13.4. Eastern Europe Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

13.5. Eastern Europe Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

13.6. Eastern Europe Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

13.7. Eastern Europe Biosimilars Market: Country Analysis

13.8. Russia Biosimilars Market

13.9. Russia Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

13.10. Russia Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

13.11. Russia Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

13.12. Russia Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

14. North America Market

14.1.1. Summary

14.2. Market Overview

14.2.1. Region Information

14.2.2. Market Information

14.2.3. Background Information

14.2.4. Government Initiatives

14.2.5. Regulations

14.2.6. Regulatory Bodies

14.2.7. Major Associations

14.2.8. Taxes Levied

14.2.9. Corporate tax structure

14.2.10. Investments

14.2.11. Major Companies

14.3. North America Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

14.4. North America Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

14.5. North America Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

14.6. North America Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

14.7. North America Biosimilars Market: Country Analysis

14.8. USA Market

14.8.1. Summary

14.9. Market Overview

14.9.1. Country Information

14.9.2. Market Information

14.9.3. Background Information

14.9.4. Government Initiatives

14.9.5. Regulations

14.9.6. Regulatory Bodies

14.9.7. Major Associations

14.9.8. Taxes Levied

14.9.9. Corporate Tax Structure

14.9.10. Investments

14.9.11. Major Companies

14.10. USA Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

14.11. USA Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

14.12. USA Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

14.13. USA Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

15. South America Market

15.1.1. Summary

15.2. Market Overview

15.2.1. Region Information

15.2.2. Market Information

15.2.3. Background Information

15.2.4. Government Initiatives

15.2.5. Regulatory Bodies

15.2.6. Regulations

15.2.7. Major Associations

15.2.8. Taxes Levied

15.2.9. Corporate Tax Structure

15.2.10. Investments

15.2.11. Major Companies

15.3. South America Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

15.4. South America Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

15.5. South America Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

15.6. South America Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

15.7. South America Biosimilars Market: Country Analysis

15.8. Brazil Biosimilars Market

15.9. Brazil Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

15.10. Brazil Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

15.11. Brazil Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

15.12. Brazil Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

16. Middle East Market

16.1.1. Summary

16.2. Market Overview

16.2.1. Region Information

16.2.2. Market Information

16.2.3. Background information

16.2.4. Government Initiatives

16.2.5. Regulatory Bodies

16.2.6. Regulations

16.2.7. Major Associations

16.2.8. Taxes Levied

16.2.9. Corporate Tax Structure

16.2.10. Investments

16.2.11. Major Companies

16.3. Middle East Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

16.4. Middle East Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

16.5. Middle East Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

16.6. Middle East Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

17. Africa Market

17.1.1. Summary

17.2. Market Overview

17.2.1. Region Information

17.2.2. Market Information

17.2.3. Background Information

17.2.4. Government Initiatives

17.2.5. Regulations

17.2.6. Regulatory Bodies

17.2.7. Major Associations

17.2.8. Taxes Levied

17.2.9. Corporate Tax Structure

17.2.10. Investments

17.2.11. Major Companies

17.3. Africa Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

17.4. Africa Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

17.5. Africa Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

17.6. Africa Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

18. Competitive Landscape And Company Profiles

18.1. Company Profiles

18.2. Amgen Inc.

18.2.1. Company Overview

18.2.2. Products And Services

18.2.3. Business Strategy

18.2.4. Financial Overview

18.3. Pfizer Inc.

18.3.1. Company Overview

18.3.2. Products And Services

18.3.3. Business Strategy

18.3.4. Financial Overview

18.4. Novartis AG

18.4.1. Company Overview

18.4.2. Products And Services

18.4.3. Business Strategy

18.4.4. Financial Overview

18.5. Samsung Bioepis Co., Ltd.

18.5.1. Company Overview

18.5.2. Products And Services

18.5.3. Business Strategy

18.5.4. Financial Overview

18.6. Viatris Inc.

18.6.1. Company Overview

18.6.2. Products And Services

18.6.3. Business Strategy

18.6.4. Financial Overview

19. Pipeline Analysis

20. Key Mergers And Acquisitions In The Biosimilars Market

20.1. Fresenius Kabi Acquired mAbxience

20.2. Biocon Biologics to Acquire Viatris Biosimilars Business

20.3. AbCellera Acquired TetraGenetics

20.4. Celltrion Acquired Assets Of Takeda Pharmaceuticals

20.5. Ligand Pharmaceuticals Acquired Pfenex

20.6. ChrysCapital Acquired Stakes In Intas Pharmaceuticals

20.7. Amgen Acquired Japanese JV with Astellas

20.8. True North Acquired Stake In Biocon Biologics Ltd.

20.9. Biocon Acquired Research and Development (R&D) Facility from Pfizer Healthcare India

20.10. PAG Acquired Hisun BioRay Bio-pharmaceutical Co., Ltd.

20.11. Pfizer Inc. Acquired Array BioPharma Inc.

20.12. Samsung Bioepis Enters Into An Agreement With C-Bridge Capital

20.13. Fuji Pharma Co., Ltd. Acquired Stake In Alvotech

20.14. Kashiv Pharma Acquired Adello Biologics

20.15. Bristol-Myers Squibb Acquired Celgene Corporation

20.16. Takeda Pharmaceutical Company Limited Acquired Shire Plc

20.17. Amneal Pharmaceuticals Merge With Impax Laboratories

20.18. Biocon Merged With Sandoz

21. Global Biosimilars Market Opportunities And Strategies

21.1. Global Biosimilars Market In 2026 – Countries Offering Most New Opportunities

21.2. Global Biosimilars Market In 2026 – Segments Offering Most New Opportunities

21.3. Global Biosimilars Market In 2026 – Growth Strategies

21.3.1. Market Trend Based Strategies

21.3.2. Competitor Strategies

22. Biosimilars Market, Conclusions And Recommendations

22.1. Conclusions

22.2. Recommendations

22.2.1. Product

22.2.2. Place

22.2.3. Price

22.2.4. Promotion

22.2.5. People

23. Appendix

23.1. Market Data Sources

23.2. Research Methodology

23.3. Currencies

23.4. The Business Research Company

24. Copyright and Disclaimer

List Of Tables

Table 1: Global Biosimilars Market, Historic, 2016 – 2021, $ Million

Table 2: Global Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million

Table 3: Global Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Table 4: Global Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million

Table 5: Global Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Table 6: Global Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million

Table 7: Global Biosimilars Market, By Region, Historic and Forecast, 2016 – 2021, 2026F, 2031F, %

Table 8: Global Biosimilars Market, By Region, Historic and Forecast, 2016 – 2021, 2026F, 2031F, $ Million

Table 9: Global Biosimilars Market, By Country, Historic and Forecast, 2016 – 2021, 2026F, 2031F, %

Table 10: Global Biosimilars Market, By Country, Historic and Forecast, 2016 – 2021, 2026F, 2031F, $ Million

Table 11: Asia-Pacific Population By Age Group, By Country, 2016-2026, Thousands

Table 12: Asia-Pacific GDP Per Capita, By Country, 2016-2021, $

Table 13: Asia-Pacific Public Healthcare Expenditure, 2015-2020, $ Billion

Table 14: Asia-Pacific Private Healthcare Expenditure, 2015-2020, $ Billion

Table 15: Asia-Pacific, Healthcare Services Market Size, By Country, 2016-2026, $ Billion

Table 16: Asia-Pacific Biosimilars Market, Historic, 2016 – 2021, $ Million

Table 17: Asia-Pacific Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million

Table 18: Asia-Pacific Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Table 19: Asia-Pacific Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million

Table 20: Asia-Pacific Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Table 21: Asia-Pacific Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million

Table 22: China Population By Age Group, 2016-2026, Thousands

Table 23: China GDP Per Capita, 2016-2021, $

Table 24: China Public Healthcare Expenditure And Private Healthcare Expenditure, 2015-2020, $ Billion

Table 25: China Healthcare Services Market Size, By Country, 2016-2026, $ Billion

Table 26: China Biosimilars Market, Historic, 2016 – 2021, $ Million

Table 27: China Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million

Table 28: China Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Table 29: China Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million

Table 30: China Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Table 31: China Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million

Table 32: India Biosimilars Market, Historic, 2016 – 2021, $ Million

Table 33: India Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million

Table 34: India Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Table 35: India Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million

Table 36: India Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Table 37: India Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million

Table 38: Japan Biosimilars Market, Historic, 2016 – 2021, $ Million

Table 39: Japan Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million

Table 40: Japan Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Table 41: Japan Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million

Table 42: Japan Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Table 43: Japan Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million

Table 44: Australia Biosimilars Market, Historic, 2016 – 2021, $ Million

Table 45: Australia Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million

Table 46: Australia Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Table 47: Australia Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million

Table 48: Australia Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Table 49: Australia Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million

Table 50: Indonesia Biosimilars Market, Historic, 2016 – 2021, $ Million

Table 51: Indonesia Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million

Table 52: Indonesia Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Table 53: Indonesia Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million

Table 54: Indonesia Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Table 55: Indonesia Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million

Table 56: South Korea Biosimilars Market, Historic, 2016 – 2021, $ Million

Table 57: South Korea Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million

Table 58: South Korea Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Table 59: South Korea Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million

Table 60: South Korea Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Table 61: South Korea Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million

Table 62: Western Europe Population By Age Group, By Country, 2016-2026, Thousands

Table 63: Western Europe GDP Per Capita, By Country, 2016-2021, $

Table 64: Western Europe Public Healthcare Expenditure, 2015-2020, $ Billion

Table 65: Western Europe Private Healthcare Expenditure, 2015-2020, $ Billion

Table 66: Western Europe Healthcare Services Market Size, By Country, 2016-2026, $ Billion

Table 67: Western Europe Biosimilars Market, Historic, 2016 – 2021, $ Million

Table 68: Western Europe Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million

Table 69: Western Europe Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Table 70: Western Europe Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million

Table 71: Western Europe Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Table 72: Western Europe Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million

Table 73: UK Biosimilars Market, Historic, 2016 – 2021, $ Million

Table 74: UK Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million

Table 75: UK Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Table 76: UK Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million

Table 77: UK Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Table 78: UK Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million

Table 79: Germany Biosimilars Market, Historic, 2016 – 2021, $ Million

Table 80: Germany Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million

Table 81: Germany Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Table 82: Germany Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million

Table 83: Germany Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Table 84: Germany Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million

Table 85: France Biosimilars Market, Historic, 2016 – 2021, $ Million

Table 86: France Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million

Table 87: France Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Table 88: France Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million

Table 89: France Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Table 90: France Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million

Table 91: Eastern Europe Population By Age Group, By Country, 2016-2026, Thousands

Table 92: Eastern Europe GDP Per Capita, By Country, 2016-2021, $

Table 93: Eastern Europe Public Healthcare Expenditure, 2015-2020, $ Billion

Table 94: Eastern Europe Private Healthcare Expenditure, 2015-2020, $ Billion

Table 95: Eastern Europe Healthcare Services Market Size, By Country, 2016-2026, $ Billion

Table 96: Eastern Europe Biosimilars Market, Historic, 2016 – 2021, $ Million

Table 97: Eastern Europe Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million

Table 98: Eastern Europe Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Table 99: Eastern Europe Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million

Table 100: Eastern Europe Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Table 101: Eastern Europe Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million

Table 102: Russia Biosimilars Market, Historic, 2016 – 2021, $ Million

Table 103: Russia Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million

Table 104: Russia Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Table 105: Russia Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million

Table 106: Russia Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Table 107: Russia Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million

Table 108: North America Population By Age Group, By Country, 2016-2026, Thousands

Table 109: North America GDP Per Capita, By Country, 2016-2021, $

Table 110: North America Public Healthcare Expenditure, 2015-2020, $ Billion

Table 111: North America Private Healthcare Expenditure, 2015-2020, $ Billion

Table 112: North America Healthcare Services Market Size, By Country, 2016-2026, $ Billion

Table 113: North America Biosimilars Market, Historic, 2016 – 2021, $ Million

Table 114: North America Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million

Table 115: North America Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Table 116: North America Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million

Table 117: North America Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Table 118: North America Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million

Table 119: USA Population By Age Group, 2016-2026, Thousands

Table 120: USA GDP Per Capita, 2016-2021, $

Table 121: USA Public Healthcare Expenditure And Private Healthcare Expenditure, 2015-2020, $ Billion

Table 122: USA Healthcare Services Market Size, By Country, 2016-2026, $ Billion

Table 123: USA Biosimilars Market, Historic, 2016 – 2021, $ Million

Table 124: USA Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million

Table 125: USA Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Table 126: USA Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million

Table 127: USA Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Table 128: USA Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million

Table 129: South America Population By Age Group, By Country, 2016-2026, Thousands

Table 130: South America GDP Per Capita, By Country, 2016-2021, $

Table 131: South America Public Healthcare Expenditure, 2015-2020, $ Billion

Table 132: South America Private Healthcare Expenditure, 2015-2020, $ Billion

Table 133: South America Healthcare Services Market Size, By Country, 2016-2026, $ Billion

Table 134: South America Biosimilars Market, Historic, 2016 – 2021, $ Million

Table 135: South America Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million

Table 136: South America Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Table 137: South America Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million

Table 138: South America Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Table 139: South America Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million

Table 140: Brazil Biosimilars Market, Historic, 2016 – 2021, $ Million

Table 141: Brazil Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million

Table 142: Brazil Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Table 143: Brazil Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million

Table 144: Brazil Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Table 145: Brazil Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million

Table 146: Middle East Population By Age Group, By Country, 2016-2026, Thousands

Table 147: Middle East GDP Per Capita, By Country, 2016-2021, $

Table 148: Middle East Public Healthcare Expenditure, 2015-2020, $ Billion

Table 149: Middle East Private Healthcare Expenditure, 2015-2020, $ Billion

Table 150: Middle East Healthcare Services Market Size, 2016-2021, $ Billion

Table 151: Middle East Biosimilars Market, Historic, 2016 – 2021, $ Million

Table 152: Middle East Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million

Table 153: Middle East Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Table 154: Middle East Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million

Table 155: Middle East Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Table 156: Middle East Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million

Table 157: Africa Population By Age Group, By Country, 2016-2026, Thousands

Table 158: Africa GDP Per Capita, By Country, 2016-2021, $

Table 159: Africa Public Healthcare Expenditure, 2015-2020, $ Billion

Table 160: Africa Private Healthcare Expenditure, 2015-2020, $ Billion

Table 161: Africa Healthcare Services Market Size, 2016-2021, $ Billion

Table 162: Africa Biosimilars Market, Historic, 2016 – 2021, $ Million

Table 163: Africa Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million

Table 164: Africa Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Table 165: Africa Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million

Table 166: Africa Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Table 167: Africa Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million

Table 168: Global Smart Wearables Market, Key Competitor Estimated Market Shares, 2021, Percentage (%)

Table 169: Amgen Inc. – Financial Overview, 2017 - 2021, $ Billion

Table 170: Pfizer Inc. – Financial Overview, 2017 - 2021, $ Billion

Table 171: Novartis AG – Financial Overview, 2017 - 2021, $ Billion

Table 172: Viatris Inc. – Financial Overview, 2017 - 2021, $ Billion

Table 173: Global Biosimilars Market, Pipeline Analysis

Table 174: Global Biosimilars Market Size Gain ($ Million), 2021 – 2026, By Country

Table 175: Global Biosimilars Market Size Gain ($ Million), Segmentation By Type, 2021 – 2026

Table 176: Global Biosimilars Market Size Gain ($ Million), Segmentation By Application, 2021 – 2026

Table 177: Biosimilars Market Data Sources

List Of Figures

Figure 1: Geographic Regions Covered

Figure 2: Global Biosimilars Market Segmentation By Type

Figure 3: Global Biosimilars Market Segmentation By Application

Figure 4: Global Biosimilars Market, Historic, 2016 – 2021, $ Million

Figure 5: Global Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million

Figure 6: Global Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 7: Global Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 8: Global Biosimilars Market, By Region, Historic and Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 9: Global Biosimilars Market, By Country, Historic and Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 10: Asia-Pacific Biosimilars Market, Historic, 2016 – 2021, $ Million

Figure 11: Asia-Pacific Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million

Figure 12: Asia-Pacific Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 13: Asia-Pacific Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 14: China Biosimilars Market, Historic, 2016 – 2021, $ Million

Figure 15: China Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million

Figure 16: China Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 17: China Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 18: India Biosimilars Market, Historic, 2016 – 2021, $ Million

Figure 19: India Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million

Figure 20: India Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 21: India Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 22: Japan Biosimilars Market, Historic, 2016 – 2021, $ Million

Figure 23: Japan Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million

Figure 24: Japan Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 25: Japan Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 26: Australia Biosimilars Market, Historic, 2016 – 2021, $ Million

Figure 27: Australia Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million

Figure 28: Australia Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 29: Australia Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 30: Indonesia Biosimilars Market, Historic, 2016 – 2021, $ Million

Figure 31: Indonesia Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million

Figure 32: Indonesia Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 33: Indonesia Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 34: South Korea Biosimilars Market, Historic, 2016 – 2021, $ Million

Figure 35: South Korea Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million

Figure 36: South Korea Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 37: South Korea Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 38: Western Europe Biosimilars Market, Historic, 2016 – 2021, $ Million

Figure 39: Western Europe Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million

Figure 40: Western Europe Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 41: Western Europe Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 42: UK Biosimilars Market, Historic, 2016 – 2021, $ Million

Figure 43: UK Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million

Figure 44: UK Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 45: UK Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 46: Germany Biosimilars Market, Historic, 2016 – 2021, $ Million

Figure 47: Germany Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million

Figure 48: Germany Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 49: Germany Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 50: France Biosimilars Market, Historic, 2016 – 2021, $ Million

Figure 51: France Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million

Figure 52: France Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 53: France Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 54: Eastern Europe Biosimilars Market, Historic, 2016 – 2021, $ Million

Figure 55: Eastern Europe Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million

Figure 56: Eastern Europe Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 57: Eastern Europe Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 58: Russia Biosimilars Market, Historic, 2016 – 2021, $ Million

Figure 59: Russia Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million

Figure 60: Russia Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 61: Russia Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 62: North America Biosimilars Market, Historic, 2016 – 2021, $ Million

Figure 63: North America Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million

Figure 64: North America Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 65: North America Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 66: USA Biosimilars Market, Historic, 2016 – 2021, $ Million

Figure 67: USA Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million

Figure 68: USA Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 69: USA Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 70: South America Biosimilars Market, Historic, 2016 – 2021, $ Million

Figure 71: South America Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million

Figure 72: South America Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 73: South America Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 74: Brazil Biosimilars Market, Historic, 2016 – 2021, $ Million

Figure 75: Brazil Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million

Figure 76: Brazil Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 77: Brazil Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 78: Middle East Biosimilars Market, Historic, 2016 – 2021, $ Million

Figure 79: Middle East Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million

Figure 80: Middle East Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 81: Middle East Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 82: Africa Biosimilars Market, Historic, 2016 – 2021, $ Million

Figure 83: Africa Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million

Figure 84: Africa Biosimilars Market, Segmentation By Type, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 85: Africa Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %

Figure 86: Global biosimilars Market, Key Competitor Estimated Market Shares, 2021, Percentage (%)

Figure 87: Amgen Inc. – Financial Overview, 2017 – 2021, $ Billion

Figure 88: Pfizer Inc. – Financial Overview, 2017 – 2021, $ Billion

Figure 89: Novartis AG – Financial Overview, 2017 – 2021, $ Billion

Figure 90: Viatris Inc. – Financial Overview, 2017 – 2021, $ Billion

The Business Research Company offers the plasma fractionation market research report 2022 with industry size, share, segments and market growth

The Business Research Company offers the hiv drugs market research report 2022 with industry size, share, segments and market growth

The Business Research Company offers the rituximab biosimilars market research report 2022 with industry size, share, segments and market growth

The Business Research Company offers the microbiome market research report 2022 with industry size, share, segments and market growth

CAR-T Therapy Market 2021 - By Target Antigen (CD19, CD22, BCMA), By Application (Acute Lymphoblastic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia, Multiple Myeloma), And By Region, Opportunities And Strategies – Global Forecast To 2030

View Report

Central Nervous System Drugs Market 2021 - By Type (Multiple Sclerosis (MS), Anti-Psychotic, Analgesics, Anti-Parkinson Drugs, Anesthetics, Anti-Epileptics, Anti-Depressants, Other CNS Drugs), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies/ Drug Stores), By Route Of Administration (Oral, Intravenous, Intranasal/ Inhalation), By Drug Classification (Branded Drugs, Generic Drugs), By Mode Of Purchase (Over-The-Counter Drugs, Prescription-Based Drugs), And By Region, Opportunities And Strategies – Global Forecast To 2030

View Report

Oral Biologics & Biosimilar Drugs Global Market Report 2024 – By Therapy (Lymphocyte Modulators, Interleukin Inhibitors, Tumor Necrosis Factor-Alpha Inhibitors), By Disease (Asthma, Crohn's Disease, Carcinoma, Arthritis, Diabetes, Multiple Myeloma, Enterocolitis, Multiple Sclerosis, Sarcoma, Psoriasis and Others), By Molecule Type (Vaccines, Proteins & Peptides, Monoclonal Antibodies, Other Molecule Types), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) – Market Size, Trends, And Global Forecast 2024-2033

View Report

Cellular Immunotherapy Global Market Report 2024 – By Therapy (Tumor-Infiltrating Lymphocyte (TIL) Therapy, Engineered T Cell Receptor (TCR) Therapy, Chimeric Antigen Receptor (CAR) T Cell Therapy, Natural Killer (NK) Cell Therapy), By Primary Indication (B-cell Malignancies, Prostate Cancer, Renal Cell Carcinoma, Liver Cancer, Non-Hodgkin lymphoma, Other Primary Indications), By Application (Prostate Cancer, Breast Cancer, Skin Cancer, Ovarian Cancer, Brain Tumor, Lung Cancer, Other Applications ) – Market Size, Trends, And Global Forecast 2024-2033

View Report

Enzymes Global Market Report 2024 – By Product Type (Asparaginase, Lipase, Protease, Nattokinase, Chitinase, Serratiopeptidase, Collagenase, Ligase, Other Products), By Application (Leukemia, Stomach Disorders, Antitumor, Skin Ulcers, Gaucher Disease, Fabry Disease, Other Applications), By End User (Drug Manufacturers, Hospitals, Private Clinics, Research Laboratories) – Market Size, Trends, And Global Forecast 2024-2033

View Report

Protein Inhibitors Global Market Report 2024 – By Product (Protein Kinase Inhibitors, Monoclonal Antibody, Other Products), By Application (Oncology, Inflammatory Diseases, Other Applications), By Distribution Channel (Hospital Pharmacies, Independent Pharmacies, Online Pharmacies ) – Market Size, Trends, And Global Forecast 2024-2033

View Report

Digestive Enzymes Global Market Report 2024 – By Enzyme Type (Carbohydrates, Protease, Lipase, Other Enzyme Types), By Origin (Animal, Fungi, Microbial, Plant), By Application (Indigestion, Chronic Pancreatitis, Irritable Bowel Syndrome, Other Applications), By Distribution Channel (Retail Stores, Online Stores) – Market Size, Trends, And Global Forecast 2024-2033

View Report

Oncology Biosimilars Global Market Report 2024 – By Drug Type (Monoclonal Antibody, Immunomodulators, Hematopoietic Agents, Granulocyte Colony-Stimulating Factor (G-CSF)), By Cancer Type (Breast Cancer, Colorectal Cancer, Blood Cancer, Neutropenia Cancer, Non-Small Cell Lung Cancer, Other Cancer Types), By Distribution Type (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) – Market Size, Trends, And Global Forecast 2024-2033

View Report

Biosimilars Global Market Opportunities And Strategies To 2031

Biosimilars Global Market Opportunities And Strategies To 2031

Biosimilars Market Definition

Biosimilars Market Size

Biosimilars Market Drivers

Biosimilars Market Restraints

Biosimilars Market Trends

Opportunities And Recommendations In The Biosimilars Market

Biosimilars Market Segmentation

Biosimilars Market Competitive Landscape

Major Competitors are:

Other Competitors Include:

Table Of Contents

List Of Tables

List Of Figures

Latest Cell Therapy Market Growth Study 2022-2026 By The Business Research Company

Global Protein Purification And Isolation Market 2022 – Market Opportunities And Strategies

What Is The Pharmaceutical Processing Seals Market Overview In 2022?

Latest Digestive Health Supplements Market Growth Study 2022-2026 By The Business Research Company

The Business Research Company offers the plasma fractionation market research report 2022 with industry size, share, segments and market growth

The Business Research Company offers the hiv drugs market research report 2022 with industry size, share, segments and market growth

The Business Research Company offers the rituximab biosimilars market research report 2022 with industry size, share, segments and market growth

The Business Research Company offers the microbiome market research report 2022 with industry size, share, segments and market growth

CAR-T Therapy Market 2021 - By Target Antigen (CD19, CD22, BCMA), By Application (Acute Lymphoblastic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia, Multiple Myeloma), And By Region, Opportunities And Strategies – Global Forecast To 2030

Frequently Asked Questions